Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Celsion Corporation

Market Cap 7.25M 6.32M 5.85M 5.48M 10.28M 684M 10.34M 69.45M 26.92M 337M 27.21M 26.63M 1.17B P/E 2026 *
-0.58x
P/E 2027 * -0.8x
Enterprise Value 7.25M 6.32M 5.85M 5.48M 10.28M 684M 10.34M 69.45M 26.92M 337M 27.21M 26.63M 1.17B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
98.4%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 56 2024-05-12
Director of Finance/CFO 69 2010-07-07
Chief Tech/Sci/R&D Officer 73 2025-02-17
Director TitleAgeSince
Chairman 75 2014-10-06
Director/Board Member 75 2011-07-07
Director/Board Member 76 2015-12-14
Change 5-day change 1-year change 3-year change Capi.($)
+1.44%-1.25%+63.52%+114.88% 55.19B
+4.60%+3.02%+58.20%+47.16% 45.75B
-1.44%+0.39%-12.94%-19.24% 22.98B
-2.69%-2.10%-3.68%+379.00% 20.76B
+3.22%-0.84%+27.88%-34.00% 16.26B
+0.58%+1.08%+16.73%-38.06% 15.42B
-1.01%-2.30%+27.42%+171.92% 13.05B
+4.95%+11.70%+123.63%+252.19% 12.45B
+3.07%+0.14%+29.37% - 12.37B
Average +1.41%+2.23%+36.68%+109.23% 23.8B
Weighted average by Cap. +1.63%+1.48%+40.92%+99.91%

Financials

2026 *2027 *
Net sales - -
Net income -16.41M -14.31M -13.25M -12.4M -23.26M -1.55B -23.4M -157M -60.92M -762M -61.59M -60.27M -2.65B -23.33M -20.34M -18.84M -17.63M -33.07M -2.2B -33.27M -223M -86.61M -1.08B -87.56M -85.69M -3.76B
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!